A Multi-Center, Open-Label, Randomized, Two-Arm Study, to Evaluate the Efficacy of Osimertinib with Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients with EGFR-Mutated NSCLC and Asymptomatic Brain Metastases